Suchergebnis | Hamburg Open Science

Facetten

18 Einträge gefunden

ETV6 rearrangements are recurrent in myeloid malignancies and are frequently associated with other genetic events.
2012 - Forschungsinformationssystem des UKE
Multilineage dysplasia does not influence prognosis in CEBPA-mutated AML, supporting the WHO proposal to classify these patients as a unique entity.
2012 - Forschungsinformationssystem des UKE
TET2 deletions are a recurrent but rare phenomenon in myeloid malignancies and are frequently accompanied by TET2 mutations on the remaining allele.
2012 - Forschungsinformationssystem des UKE
Use of CBL exon 8 and 9 mutations in diagnosis of myeloproliferative neoplasms and myelodysplastic/myeloproliferative disorders: an analysis of 636 cases.
2012 - Forschungsinformationssystem des UKE - frei zugänglich
Amount of bone marrow blasts is strongly correlated to NPM1 and FLT3-ITD mutation rate in AML with normal karyotype.
2012 - Forschungsinformationssystem des UKE
Monoclonal B-cell lymphocytosis is closely related to chronic lymphocytic leukaemia and may be better classified as early-stage CLL.
2012 - Forschungsinformationssystem des UKE
Molecular analyses of 15,542 patients with suspected BCR-ABL1-negative myeloproliferative disorders allow to develop a stepwise diagnostic workflow.
2012 - Forschungsinformationssystem des UKE - frei zugänglich
Frequency and prognostic impact of the aberrant CD8 expression in 5,523 patients with chronic lymphocytic leukemia.
2012 - Forschungsinformationssystem des UKE
Prognoses of MDS subtypes RARS, RCMD and RCMD-RS are comparable but cytogenetics separates a subgroup with inferior clinical course.
2012 - Forschungsinformationssystem des UKE
Subclones with the t(9;22)/BCR-ABL1 rearrangement occur in AML and seem to cooperate with distinct genetic alterations.
2011 - Forschungsinformationssystem des UKE
Clinical impact of FLT3 mutation load in acute promyelocytic leukemia with t(15;17)/PML-RARA.
2011 - Forschungsinformationssystem des UKE - frei zugänglich
Comparison of genetic and clinical aspects in patients with acute myeloid leukemia and myelodysplastic syndromes all with more than 50% of bone marrow erythropoietic cells.
2011 - Forschungsinformationssystem des UKE - frei zugänglich
Several lymphoma-specific genetic events in parallel can be found in mature B-cell neoplasms.
2011 - Forschungsinformationssystem des UKE
CDKN1B, encoding the cyclin-dependent kinase inhibitor 1B (p27), is located in the minimally deleted region of 12p abnormalities in myeloid malignancies and its low expression is a favorable prognostic marker in acute myeloid leukemia.
2011 - Forschungsinformationssystem des UKE - frei zugänglich
Biological and clinical characterization of recurrent 14q deletions in CLL and other mature B-cell neoplasms.
2010 - Forschungsinformationssystem des UKE
Associations between imatinib resistance conferring mutations and Philadelphia positive clonal cytogenetic evolution in CML.
2010 - Forschungsinformationssystem des UKE
Correlation of cytomorphology, immunophenotyping, and interphase fluorescence in situ hybridization in 381 patients with monoclonal gammopathy of undetermined significance and 301 patients with plasma cell myeloma.
2010 - Forschungsinformationssystem des UKE
Comparison of cytogenetic clonal evolution patterns following allogeneic hematopoietic transplantation versus conventional treatment in patients at relapse of AML.
2010 - Forschungsinformationssystem des UKE

Aktive Facetten

Facetten

Zugriff

Einrichtung

Medientyp

Karte

Erscheinungsjahr

Autor/in

Sprache

ETV6 rearrangements are recurrent in myeloid malignancies and are frequently associated with other genetic events.

Multilineage dysplasia does not influence prognosis in CEBPA-mutated AML, supporting the WHO proposal to classify these patients as a unique entity.

TET2 deletions are a recurrent but rare phenomenon in myeloid malignancies and are frequently accompanied by TET2 mutations on the remaining allele.

Use of CBL exon 8 and 9 mutations in diagnosis of myeloproliferative neoplasms and myelodysplastic/myeloproliferative disorders: an analysis of 636 cases.

Amount of bone marrow blasts is strongly correlated to NPM1 and FLT3-ITD mutation rate in AML with normal karyotype.

Monoclonal B-cell lymphocytosis is closely related to chronic lymphocytic leukaemia and may be better classified as early-stage CLL.

Molecular analyses of 15,542 patients with suspected BCR-ABL1-negative myeloproliferative disorders allow to develop a stepwise diagnostic workflow.

Frequency and prognostic impact of the aberrant CD8 expression in 5,523 patients with chronic lymphocytic leukemia.

Prognoses of MDS subtypes RARS, RCMD and RCMD-RS are comparable but cytogenetics separates a subgroup with inferior clinical course.

Subclones with the t(9;22)/BCR-ABL1 rearrangement occur in AML and seem to cooperate with distinct genetic alterations.

Clinical impact of FLT3 mutation load in acute promyelocytic leukemia with t(15;17)/PML-RARA.

Comparison of genetic and clinical aspects in patients with acute myeloid leukemia and myelodysplastic syndromes all with more than 50% of bone marrow erythropoietic cells.

Several lymphoma-specific genetic events in parallel can be found in mature B-cell neoplasms.

CDKN1B, encoding the cyclin-dependent kinase inhibitor 1B (p27), is located in the minimally deleted region of 12p abnormalities in myeloid malignancies and its low expression is a favorable prognostic marker in acute myeloid leukemia.

Biological and clinical characterization of recurrent 14q deletions in CLL and other mature B-cell neoplasms.

Associations between imatinib resistance conferring mutations and Philadelphia positive clonal cytogenetic evolution in CML.

Correlation of cytomorphology, immunophenotyping, and interphase fluorescence in situ hybridization in 381 patients with monoclonal gammopathy of undetermined significance and 301 patients with plasma cell myeloma.

Comparison of cytogenetic clonal evolution patterns following allogeneic hematopoietic transplantation versus conventional treatment in patients at relapse of AML.